نوع مقاله : مقاله پژوهشی
نویسندگان
1 کارشناس ارشد بیوشیمی، دانشگاه پیام نور، تهران، ایران
2 استاد تمام بیوشیمی، دانشگاه پیام نور، تهران، ایران
3 استادیار بیوشیمی، دانشگاه پیام نور، تهران، ایران
چکیده
زمینه و هدف: پاندمــی کوویــد-۱9 کــه توســط کرونــاویــروس ایجاد شده به یکی از بزرگترین مشکلات بهداشــتی قرن حاضر تبدیل شــده اســت. نقش دادههای آزمایشگاهی در تشخیص اشکال شدید کووید-19 بهطور قطع ثابت نشده است. این پژوهش با هدف یافتن راههای پیشگیری سریع بیماری کووید-19 انجام شد.
مواد و روشها: : این مطالعه بر روی 43 نفر از بیماران کووید-19 از اسفند1400 تا اردبیهشت 1401 در مرکز خصوصی مهرگان استان خوزستان انجام شد .آزمایشهای هماتولوژیک و بیوشیمیایی بیماران انجام شد. برای بهدستآوردن مقدار متغیرها ازجمله دی-دایمر و اینترلوکین6 از دستگاه الایزا (Biotek ELX 800TS) و برای فیبرینوژن از روش انعقاد Clauss استفاده شد. تجزیهوتحلیل دادهها با اسـتفاده از نرمافزار آماری spssورژن 22 و Graph pad prismورژن 9 انجام شد.
یافتهها: : یافتهها تفاوت معنیداری در میزان اینترلوکین۶، دی-دایمر و فیبرینوژن نشان داد که این میزان برابر با 0.0001 بود (P <0.05). سطح آستانه و مساحت زیرمنحنی مشخصه عملکرد گیرنده اینترلوکین6 بهترتیب 20/06 پیکوگرم/میلیلیتر و837 /0، دی-دایمر 952/5 نانوگرم/میلیلیتر و 0/929 و فیبرینوژن 206/5 میلیگرم/دسی لیتر و 0/768 بود. ویژگی و حساسیت پیشبینی شدت کووید-19 اینترلوکین 6 بهترتیب 67/44 درصد و 100 درصد، دی-دایمر 60/47 درصد و 97/67 درصد و فیبرینوژن 53/49 درصد و35 /95 درصد بود. اینترلوکین6 و دی-دایمر دارای بالاترین ویژگی و حساسیت برای پیشبینی اولیه شدت کووید-19 بودند اما برای فیبرینوژن این میزان به اندازه دو فاکتور دیگر آشکار نبود.
نتیجهگیری: بهترتیب دی- دایمر و اینترلوکین 6 دارای بیشترین تأثیرات و فیبرینوژن کمترین تأثیر را در شدت این بیماری داشتند.
تازه های تحقیق
https://scholar.google.com/citations?hl=en&user=8sVMSNMAAAAJ
https://pubmed.ncbi.nlm.nih.gov/term=mahsa
https://scholar.google.com/citations?user=0R4shdoAAAAJ&hl=en
https://pubmed.ncbi.nlm.nih.gov/term=mohammad
https://scholar.google.com/citations?user=0GBL7C8AAAAJ&hl=en
https://pubmed.ncbi.nlm.nih.gov/term=Zolfaghar
کلیدواژهها
موضوعات
عنوان مقاله [English]
Examining the Serum Levels of D-Dimer, Fibrinogen, and Interleukin-6 as Indicators for Timely Treatment of COVID-19 Patients
نویسندگان [English]
- mahsa saeedpour 1
- mohamad fazilati 2
- zolfaghar lotfi 3
1 Master’s student, Department of Basic Sciences, Payam Noor University, Tehran, Iran
2 Professor, Department of Basic Sciences, Payam Noor University, Tehran, Iran
3 Assistant Professor, Department of Basic Sciences, Payam Noor University, Tehran, Iran
چکیده [English]
Introduction: The COVID-19 pandemic, caused by the coronavirus, has emerged as one of the most pressing healthcare challenges of this century. The role of laboratory data in diagnosing severe forms of COVID-19 remains inconclusive. This research aimed to find ways to quickly prevent COVID-19.
Materials and Methods: This research involved 43 COVID-19 patients monitored from March 2022 to May 2022 at the Mehregan Private Center in Khuzestan Province. Hematological and biochemical tests of the patients were performed. Measurements of D-dimer and Interleukin-6 were performed using the Biotek ELX 800TS analyzer, while fibrinogen levels were determined through the Clauss coagulation method. Data analysis was carried out using SPSS version 22 and GraphPad Prism version 9.
Results: There is a significant difference in the levels of interleukin 6, D-Dimer, and fibrinogen, which was equal to 0.0001 (P<0.05). Threshold level and area under the receptor operating characteristic curve (ROC) interleukin-6 was 20.06 pg/ml and 0.837, D-dimer 952.5 ng/ml and 0.929, and fibrinogen was 206.5 mg/dL and 0.768, respectively. The specificity and sensitivity of predicting the severity of COVID-19 interleukin 6 were 67.44% and 100%, D-dimer 60.47% and 97.67%, and fibrinogen 53.49 % and 95.35%, respectively. Interleukin-6 and D-dimer had the highest specificity and sensitivity for early prediction of the severity of COVID-19, but for fibrinogen, this level was not as obvious as the other two factors.
Conclusion: D-dimer and interleukin-6 had more pronounced effects on the severity of this disease, while fibrinogen had a lower impact.
کلیدواژهها [English]
- COVID-19 SARS-C0V-2
- interleukin fibrinogen
- Fibrin Fibrinogen Degradation Products
- Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses: methods and protocols. 2015:1-23. DOI: 10.1007/978-1-4939-2438-7_1
- Woo PC, Lau SK, Choi GK, Huang Y, Teng JL, Tsoi HW, et al. Natural occurrence and characterization of two internal ribosome entry site elements in a novel virus, canine Pico dicistrovirus, in the picornavirus-like superfamily. Journal of virology. 2012 Mar 1;86(5):2797-808. DOI: 10.1128/JVI.05481-11
- Hayıroğlu Mİ, Çınar T, Tekkeşin Aİ. Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review. Revista da Associação Médica Brasileira. 2020Jul20;66: 842-8.DOI:10.1590/1806-9282.66.6.842
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet. 2020Feb15;395(10223):507-13. https://doi.org/10.1016/s0140-6736(20)30211-7
- Lokwani DP, Yadav BS, Bharti S, Gupta V, Toppo N. Evaluation of hematological, coagulation and inflammatory biomarker's role in predicting the severity of disease in patients with COVID-19, admitted in designated COVID-19 hospital of central India. Indian Journal of Pathology and Microbiology. 2021 Oct 1;64(4):735-40. Doi: 10.4103/IJPM.IJPM_1350_20.
- Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood, The Journal of the American Society of Hematology. 2015 Feb 26;125(9):1387-93.https://doi.org/10.1182/blood-2014-08-552000
- Collen D, Tytgat GN, Claeys H, Piessens R. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. British journal of haematology. 1972 Jun;22(6):681-700. https://doi.org/10.1111/j.1365-2141.1972.tb05715.x
- Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. Journal of the American College of Cardiology. 2017 Nov 7;70(19):2411-20. https://doi.org/10.1016/j.jacc.2017.09.024
- Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harbor perspectives in biology. 2014 Oct 1;6(10): a016295.Doi: 10.1101/cshperspect. a016295
- Grifoni E, Valoriani A, Cei F, Lamanna R, Gelli AM, Ciambotti B, et al. Interleukin-6 as prognosticator in patients with COVID-19. Journal of Infection. 2020 Sep 1;81(3):452-82. https://doi.org/10.1016/j.jinf.2020.06.008
- Tayal V, Kalra BS. Cytokines and anti-cytokines as therapeutics—An update. European journal of pharmacology. 2008 Jan 28;579(1-3):1-2. https://doi.org/10.1016/j.ejphar.2007.10.049
- Uciechowski P, Dempke W. Interleukin-6: a Masterplayer in the cytokine network. Oncology. 2020 Feb 26;98(3):131-7. Doi: 10.1159/000505099. Pub 2020 Jan 20
- Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. Journal of Clinical Virology. 2020 Jun 1;127: 104362.104362.DOI: https://doi.org/10.1016/S0140-6736(20)30211-7
- Li X, Li J, Ge Q, Du Y, Li G, Li W, et al. Detecting SARS-CoV-2 in the breath of COVID-19 patients. Frontiers in Medicine. 2021 Mar 17; 8:604392. DOI: 10.3389/fmed.2021.604392
- Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS one. 2021 Aug 26;16(8): e0256744. https://doi.org/10.1371/journal.pone.0256744
- Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐ Journal of thrombosis and hemostasis. 2020 Jun 1;18(6):1324-9. https://doi.org/10.1111/jth.14859
- Soni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020 Nov 1;14(6):2245-9. https://doi.org/10.1016/j.dsx.2020.11.00
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020 Mar 17;323(11):1061-9. doi:10.1001/jama.2020.1585
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020 Mar 28;395(10229):1054-62. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3
- Shah S, Shah K, Patel SB, Patel FS, Osman M, Velagapudi P, et al. Elevated D-dimer levels are associated with increased risk of mortality in coronavirus disease 2019: a systematic review and meta-analysis. Cardiology in review. 2020 Aug 8. Doi: 10.1097/CRD.0000000000000330
- Naymagon L, Zubizarreta N, Feld J, van Gerwen M, Alsen M, Thibaud S, et al. Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19. Thrombosis research. 2020 Dec 1; 196:99-105. https://doi.org/10.1016/j.thromres.2020.08.032
- Patil S, Gondhali G, Acharya A. Role of interleukin-6 in coronavirus disease 2019 pneumonia: sensitive marker of inflammation, a predictor of ventilatory support and early marker of post-coronavirus disease lung fibrosis. A single center experience. The Egyptian Journal of Chest Diseases and Tuberculosis. 2023 Jul 1;72(3): 346-54.DOI: 10.4103/ecdt.ECDT_48_22
- Aziz M, Fatima R, Assaly R. Elevated interleukin‐6 and severe COVID‐19: a meta‐ Journal of medical virology. 2020 Nov;92(11):2283. Doi: 10.1002/jmv.25948
- Eljilany I, Elzouki AN. D-dimer, fibrinogen, and IL-6 in COVID-19 patients with suspected venous thromboembolism: a narrative review. Vascular health and risk management. 2020 Nov 13:455-62. https://doi.org/10.2147/VHRM.S280962
- Farid E, Sridharan K, Alsegai OA, Khawaja SA, Mansoor EJ, Teraifi NA, et al. Utility of inflammatory biomarkers in patients with COVID-19 infections: Bahrain experience. Biomarkers in Medicine. 2021 Jun;15(8):541-9. https://doi.org/10.2217/bmm-2020-0422
- Sivakorn C, Dechsanga J, Jamjumrus L, Boonnak K, Schultz MJ, Dondorp AM, et al. High mobility group box 1 and interleukin 6 at intensive care unit admission as biomarkers in critically ill COVID-19 patients. The American Journal of Tropical Medicine and Hygiene. 2021 Jul;105(1):73. Doi: 10.4269/ajtmh.21-0165
- Chandel A, Patolia S, Looby M, Bade N, Khangoora V, King CS. Association of D-dimer and fibrinogen with hypercoagulability in COVID-19 requiring extracorporeal membrane oxygenation. Journal of intensive care medicine. 2021Jun;36(6):689-95. https://doi.org/10.1177/0885066621997039
- McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmunity reviews. 2020 Jun 1;19(6):102537. https://doi.org/10.1016/j.autrev.2020.102537.
- Vanni G, Materazzo M, Dauri M, Farinaccio A, Buonomo C, Portarena I, et al. Lymphocytes, interleukin 6 and d-dimer cannot predict clinical outcome in coronavirus cancer patients: LyNC1. 20 study. Anticancer Research. 2021 Jan 1;41(1): 307-16.DOI https://doi.org/10.21873/anticanres.14777
- Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS‐CoV‐2: a systematic review and meta‐ Journal of medical virology. 2020Sep;92(9):1449-59. https://doi.org/10.1002/jmv.25822
- Vivan MA, Rigatti B, Cunha SV, Frison GC, Antoniazzi LQ, Oliveira PH, et al. Pulmonary embolism in patients with COVID-19 and D-dimer diagnostic value: A retrospective study. Brazilian Journal of Infectious Diseases. 2023 Jan 23;26. https://doi.org/10.1016/j.bjid.2022.102702
- Patil S, Khule S, Toshniwal S. Role of D-Dimer in assessing severity, monitoring, and predicating outcome in COVID-19 pneumonia: A single center study. Glob J Health Sci Res. 2023 Jan; 1:31-7. DOI:10.25259/GJHSR_11_2023
- Akkoc G, Agbas A, Göksu E, Beyaz S, Yildiz F, Bayramoglu E, et al. SARS-COV-2 infections in children: The role of fibrinogen in predicting diagnosis and severity: A retrospective cohort study. Adv. clin. exp. med. 2023 May 16. Doi: 10.17219/acem/163410
- de Vries JJ, Visser C, van Ommen M, Rokx C, van Nood E, van Gorp EC, et al. Levels of Fibrinogen Variants Are Altered in Severe COVID-19. TH Open: Companion Journal to Thrombosis and Haemostasias. 2023 Jul;7(3): e217. Doi: 10.1055/a-2102-4521
- Onuk S, Sipahioğlu H, Karahan S, Yeşiltepe A, Kuzugüden S, Karabulut A, et al. Cytokine levels and severity of illness scoring systems to predict mortality in COVID-19 infection. In Healthcare 2023 Jan 29 (Vol. 11, No. 3, p. 387). MDPI. https://doi.org/10.3390/healthcare11030387
- Urazov S, Chernov A, Popov O, Klenkova N, Sushentseva N, Polkovnikova I, et al. Secretory Phospholipase A2 and Interleukin-6 Levels as Predictive Markers of the Severity and Outcome of Patients with COVID-19 Infections. International Journal of Molecular Sciences. 2023 Mar 14;24(6):5540. https://doi.org/10.3390/ijms24065540
- Yin JX, Agbana YL, Sun ZS, Fei SW, Zhao HQ, Zhou XN, et al. Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis. Infectious Diseases of Poverty. 2023 Dec;12(1):1-4.https://doi.org/10.1186/s40249-023-01086-z